UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q

(Mark One)

ý	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 26, 2003

OR

o	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number 0-23651



First Consulting Group, Inc.
(Exact name of registrant as specified in its charter)

Delaware		95-3539020
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

111 W. Ocean Blvd., 4^th Floor, Long Beach, CA 90802
(Address of principal executive offices including zip code)

(562) 624-5200
(Registrant’s telephone number, including area code)



(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ý No o

Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act). Yes ý No o

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

Common Stock, $.001 par value		25,946,072
(Class)		(Outstanding at October 24, 2003)

First Consulting Group, Inc.

Table of Contents

COVER PAGE

TABLE OF CONTENTS

PART I.				FINANCIAL INFORMATION

		ITEM 1. FINANCIAL STATEMENTS AND NOTES (UNAUDITED)

			Consolidated Balance Sheets

			Consolidated Statements of Operations

			Consolidated Statements of Cash Flows

			Notes to Consolidated Financial Statements

	ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

	ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS

	ITEM 4. CONTROLS AND PROCEDURES

PART II. OTHER INFORMATION

	ITEM 1. LEGAL PROCEEDINGS.

	ITEM 2. CHANGES IN SECURITIES.

	ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

	ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

	ITEM 5. OTHER INFORMATION.

	ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K.

SIGNATURES

EXHIBIT INDEX

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements and Notes (Unaudited)

First Consulting Group, Inc. and Subsidiaries

Consolidated Balance Sheets

(in thousands, except share data)

	September 26, 2003		December 27, 2002
	(unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	22,725	$	27,550
Short-term investments	33,742		38,796
Accounts receivable, less allowance of $1,901 and $1,899 in the periods ended September 26, 2003 and December 27, 2002, respectively	23,392		36,889
Unbilled receivables	14,927		13,264
Deferred income taxes	6,163		6,198
Prepaid expenses and other current assets	1,894		2,110
Total current assets	102,843		124,807

Notes receivable – stockholders	594		657
Long-term investments	3,219		2,200
Property and equipment:
Furniture, equipment, and leasehold improvements	5,533		7,505
Information systems equipment	23,532		21,123
	29,065		28,628
Less accumulated depreciation and amortization	19,645		20,104
	9,420		8,524

Other assets:
Executive benefit trust	5,818		6,059
Long-term account receivable	6,189		8,059
Deferred income taxes	9,018		3,147
Goodwill, net	15,076		3,282
Intangibles, net	4,671		214
Other	1,474		360
	42,246		21,121
Total assets	$	158,322	$	157,309

The accompanying notes are an integral part of these financial statements.

	September 26, 2003			December 27, 2002
	(unaudited)
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	2,888		$	1,652
Accrued liabilities	16,935			14,660
Accrued restructuring	8,184			7,578
Accrued vacation	7,208			6,868
Accrued incentive compensation	2,081			2,328
Customer advances	6,714			7,877
Total current liabilities	44,010			40,963
Non-current liabilities:
Supplemental executive retirement plan	5,937			6,351
Minority interest	443			2,023
Total non-current liabilities	6,380			8,374
Commitments and contingencies	—			—
Stockholders’ equity:
Preferred Stock, $.001 par value; 9,500,000 shares authorized, no shares issued and outstanding	—			—
Series A Junior Participating Preferred Stock, $.001 par value; 500,000 shares authorized, no shares issued and outstanding	—			—
Common Stock, $.001 par value; 50,000,000 shares authorized, 25,934,536 and 24,073,089 shares issued and outstanding at September 26, 2003 and December 27, 2002, respectively	26			24
Additional paid-in capital	101,791			92,461
Retained earnings	7,860			17,853
Deferred compensation-stock incentive agreements	(409		)	(621		)
Notes receivable-stockholders	(732		)	(1,076		)
Accumulated other comprehensive loss	(604		)	(669		)
Total stockholders’ equity	107,932			107,972
Total liabilities and stockholders’ equity	$	158,322		$	157,309

The accompanying notes are an integral part of these financial statements.

First Consulting Group, Inc. and Subsidiaries

Consolidated Statements of Operations

(in thousands, except per share data)

	Three Months Ended						Nine Months Ended
	(unaudited)						(unaudited)
	September 26, 2003			September 27, 2002			September 26, 2003			September 27, 2002

Revenues before reimbursements	$	65,849		$	69,606		$	207,289		$	199,081
Reimbursements	4,060			3,487			11,725			11,301
Total revenues	69,909			73,093			219,014			210,382

Cost of services before reimbursable expenses	46,709			45,762			142,999			127,644
Reimbursable expenses	4,060			3,487			11,725			11,301
Total cost of services	50,769			49,249			154,724			138,945

Gross profit	19,140			23,844			64,290			71,437

Selling expenses	6,702			7,079			21,670			20,912
General and administrative expenses	15,326			13,471			46,501			42,953
Restructuring, severance, and impairment costs	4,179			—			8,093			7,818
Income (loss) from operations	(7,067		)	3,294			(11,974		)	(246		)
Other income (expense):
Interest income, net	232			240			760			692
Other expense, net	(160		)	(233		)	(164		)	(340		)
Income (loss) before income taxes and cumulative effect of change in accounting principle, net of tax	(6,995		)	3,301			(11,378		)	106
Income tax (benefit) expense	(2,448		)	1,390			(3,982		)	44
Income (loss) before cumulative effect of change in accounting principle, net of tax	(4,547		)	1,911			(7,396		)	62
Cumulative effect of change in accounting principle, net of tax	—			—			(2,597		)	—
Net income (loss)	$	(4,547	)	$	1,911		$	(9,993	)	$	62

Basic & diluted income (loss) per share
Income (loss) before cumulative effect of change in accounting principle, net of tax	$	(0.18	)	$	0.08		$	(0.30	)	$	0.00
Cumulative effect of change in accounting principle, net of tax	—			—			(0.10		)	—
Net income (loss)	$	(0.18	)	$	0.08		$	(0.40	)	$	0.00
Weighted average shares used in computing:
Basic income (loss) per share	24,944			24,074			24,752			23,976
Diluted income (loss) per share	24,944			24,535			24,752			24,826

The accompanying notes are an integral part of these financial statements.

First Consulting Group, Inc. and Subsidiaries

Consolidated Statements of Cash Flows

(in thousands)

	Nine Months Ended
	(unaudited)
	September 26, 2003			September 27, 2002
Cash flows from operating activities:
Net income (loss):	$	(9,993	)	$	62
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Cumulative effect of change in accounting principle, net of tax	2,597			—
Depreciation and amortization	4,303			3,890
Goodwill impairment	—			2,143
Provision for bad debts, net of adjustments	(20		)	(379		)
Loss (gain) on sale of assets	(15		)	(4		)
Minority interest in net income (loss) of subsidiaries	88			405
Compensation from stock issuances	128			77
Interest income on notes receivable – stockholders	(85		)	(254		)
Changes in assets and liabilities, excluding effect of acquisitions:
Accounts receivable	14,714			9,376
Unbilled receivables	(6,494		)	(6,298		)
Prepaid expenses and other	239			230
Long-term account receivable	1,230			1,185
Other assets	(331		)	(421		)
Accounts payable	1,146			736
Accrued liabilities	3,440			2,942
Accrued restructuring	717			639
Accrued vacation	268			484
Accrued incentive compensation	(247		)	(2,406		)
Customer advances	(1,223		)	(47		)
Deferred income taxes	(5,836		)	233
Supplemental executive retirement plan	(414		)	208
Other	335			421
Net cash provided by operating activities:	4,547			13,222
Cash flows from investing activities:
Proceeds from sale/maturity of investments	4,035			(321		)
Purchase of property and equipment	(4,160		)	(1,987		)
Acquisition of businesses, net of cash acquired	(11,155		)	(2,656		)
Net cash used in investing activities	(11,280		)	(4,964		)
Cash flows from financing activities:
Proceeds from issuance of capital stock, net	1,375			2,158
Proceeds from notes receivable and tax loan payments	533			211
Net cash provided by financing activities	1,908			2,369
Net change in cash and cash equivalents	(4,825		)	10,627
Cash and cash equivalents at beginning of period	27,550			32,499
Cash and cash equivalents at end of period	$	22,725		$	43,126

Cash paid during the period for:
Interest	$	27		$	32
Income taxes	$	311		$	956

The accompanying notes are an integral part of these financial statements.

Notes to Consolidated Financial Statements

1. Accounting Policies

Basis of Presentation

The consolidated balance sheet of First Consulting Group, Inc. (the “Company”) at September 26, 2003 and consolidated statements of operations and consolidated statements of cash flows for the periods ended September 26, 2003 and September 27, 2002 are unaudited. These financial statements reflect all adjustments, consisting of only normal recurring adjustments, which, in the opinion of management, are necessary to fairly present the financial position of the Company at September 26, 2003, the results of operations for the three month and nine month periods ended September 26, 2003 and September 27, 2002 and the cash flows for the nine month periods ended September 26, 2003 and September 27, 2002. The results of operations and cash flows for the nine months ended September 26, 2003 are not necessarily indicative of the results to be expected for the year ending December 26, 2003. For more complete financial information, these financial statements should be read in conjunction with the audited financial statements for the year ended December 27, 2002 included in the Company’s Annual Report on Form 10-K.

Principles of Consolidation

The consolidated financial statements include the accounts of First Consulting Group, Inc. and its subsidiaries. All material intercompany accounts and transactions have been eliminated.

Stock-Based Compensation

The Company accounts for stock-based employee compensation as prescribed by APB Opinion No. 25, “Accounting for Stock Issued to Employees,” and has adopted the disclosure provisions of Statement of Financial Accounting Standards No. 123, “Accounting for Stock-Based Compensation” (“SFAS No. 123”), and Statement of Financial Accounting Standards No. 148, “Accounting for Stock-Based Compensation – Transition and Disclosure – an amendment of SFAS No. 123” (“SFAS No. 148”). SFAS No. 123 requires pro forma disclosures of net income (loss) and net income (loss) per share as if the fair value based method of accounting for stock-based awards had been applied. Under the fair value based method, compensation cost is recorded based on the value of the award at the grant date and is recognized over the service period.

The following table presents pro forma net income (loss) had compensation costs been determined on the fair value at the date of grant for awards under the plan in accordance with SFAS No. 123 (in thousands, except per share data):

	Three Months Ended						Nine Months Ended
	September 26, 2003			September 27, 2002			September 26, 2003			September 27, 2002
Net income (loss), as reported	$	(4,547	)	$	1,911		$	(9,993	)	$	62
Deduct: Total stock based employee compensation expense determined under fair value method for all awards, net of tax	(274		)	(477		)	(1,676		)	(2,197		)
Pro forma net income (loss)	$	(4,821	)	$	1,434		$	(11,669	)	$	(2,135	)

Basic & diluted income (loss) per share As reported	$	(0.18	)	$	0.08		$	(0.40	)	$	0.00
Pro forma	$	(0.19	)	$	0.06		$	(0.47	)	$	(0.09	)

Basic and Diluted Net Income (Loss) Per Share

Basic net income (loss) per share is based upon the weighted average number of common shares outstanding. Diluted net income per share is based on the assumption that stock options were converted or exercised. Dilution is computed by applying the treasury stock method. Under this method, options are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase common stock at the average market price during the period. Stock options are not considered when computing diluted net loss per share as they are considered anti-dilutive.

The following represents a reconciliation of basic and diluted net income (loss) per share for the three month and nine month periods ended September 26, 2003 and September 27, 2002 (in thousands, except per share data):

	Three Months Ended					Nine Months Ended
	September 26, 2003			September 27, 2002		September 26, 2003			September 27, 2002

Income (loss) before cumulative effect, net of tax	$	(4,547	)	$	1,911	$	(7,396	)	$	62
Cumulative effect of change in accounting principle, net of tax	—			—		2,597			—
Net income (loss)	$	(4,547	)	$	1,911	$	(9,993	)	$	62

Basic & diluted income (loss) per share:
Income (loss) before cumulative effect, net of tax	$	(0.18	)	$	0.08	$	(0.30	)	$	0.00
Cumulative effect of change in accounting principle, net of tax	—			—		(0.10		)	—
Net income (loss) per share	$	(0.18	)	$	0.08	$	(0.40	)	$	0.00

Basic weighted number of shares outstanding	24,944			24,074		24,752			23,976
Effect of dilutive options and warrants	—			461		—			850
Diluted weighted number of shares outstanding	24,944			24,535		24,752			24,826

Use of Estimates

In preparing financial statements in conformity with accounting principles generally accepted in the United States, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. On an on-going basis, the Company evaluates its estimates, including those related to revenue recognition, valuation of goodwill and long-lived and intangible assets, accrued liabilities, income taxes including the potential need for a tax asset valuation allowance, restructuring costs, litigation and disputes, and the allowance for doubtful accounts. The Company uses significant estimates in the calculation of its income tax benefit by estimating that it will have sufficient future taxable income to realize its deferred tax assets in full and does not need to record a valuation allowance at this time. However, there can be no assurances that the Company’s taxable income will be sufficient to realize such deferred tax assets and the Company will continue to evaluate the potential need for a valuation allowance on an ongoing basis.

The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. The Company’s actual results may differ from its estimates.

Recent Accounting Pronouncement

In June 2002, the Financial Accounting Standards Board (“FASB”) issued SFAS No. 146, “Accounting for Costs Associated with Exit or Disposal Activities.” SFAS No. 146 addresses accounting and reporting costs associated with exit or disposal activities and nullifies Emerging Issues Task Force (EITF) Issue 94-3, “Liability Recognition for Certain Employee Termination Benefits and Other Costs to Exit an Activity.” SFAS No. 146 requires that a liability for a cost associated with an exit or disposal activity shall be recognized and measured initially at its fair value in the period that the liability is incurred. SFAS No. 146 is effective for exit or disposal activities that are initiated after December 31, 2002. SFAS No. 146 affected the Company’s restructuring charges in the second and third quarters of fiscal year 2003, as it accrued only severance related to employees terminated during the quarter, and not any severance related to planned future actions. As a result, the Company will record additional severance costs as incurred in the fourth quarter of 2003.

In November 2002, the EITF reached a consensus on Issue 00-21, titled “Accounting for Revenue Arrangements with Multiple Deliverables,” which addresses how to account for arrangements that involve the delivery or performance of multiple products, services, and/or rights to use assets. Revenue arrangements with multiple deliverables are divided into separate units of accounting if the deliverables in the arrangement meet the following criteria: (1) the delivered item has value to the customer on a standalone basis; (2) there is objective and reliable evidence of the fair value of undelivered items; and (3) delivery of any undelivered item is probable. Arrangement consideration should be allocated among the separate units of accounting based on their relative fair values, with the amount allocated to the delivered item being limited to the amount that is not contingent on the delivery of additional items or meeting other specified performance conditions. The new standard was required to be adopted for all new applicable revenue arrangements no later than the third quarter of 2003. Early adoption was permitted and the Company adopted the new standard as of the beginning of 2003. In addition, the Company adopted the new standard to all existing outsourcing arrangements impacted by EITF 00-21 and recorded the resulting cumulative effect as a change in accounting principle. The non-cash charge, net of tax, was $2.6 million, or $0.11 per share, which was recorded in the first quarter of 2003. At September 26, 2003, the per share charge equates to $0.10 due to the increase in the number of shares outstanding.

In November 2002, the FASB issued Interpretation No. 45 (“FIN 45”), “Guarantor’s Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantees and Indebtedness of Others.” FIN 45 elaborates on the disclosures to be made by the guarantor in its interim and annual financial statements about its obligations under certain guarantees that it has issued. It also requires that a guarantor recognize, at the inception of a guarantee, a liability for the fair value of the obligation undertaken in issuing the guarantee. The initial recognition and measurement provisions of this interpretation are applicable on a prospective basis to guarantees issued or modified after December 31, 2002; while the provisions of the disclosure requirements are effective for financial statements of interim or annual reports ending after December 15, 2002. At September 26, 2003, the Company had no guarantees outstanding.

In December 2002, the FASB issued SFAS No. 148, “Accounting for Stock-Based Compensation-Transition and Disclosure.” SFAS No. 148 amends SFAS No. 123, “Stock-Based Compensation,” to provide alternative methods of transition for a voluntary change to the fair value based method of accounting for stock-based employee compensation. In addition, SFAS No. 148 amends the

disclosure requirements of SFAS No. 123 to require prominent disclosures in both annual and interim financial statements about the method of accounting for stock-based employee compensation and the effect of the method used on reported results. The disclosure provisions of SFAS No. 148 are effective for fiscal years ending after December 15, 2002. At this time, the Company intends to continue to account for stock-based compensation to its associates using the methods prescribed by Accounting Principles Bulletin (APB) Opinion No. 25, and related interpretations. The Company has made certain disclosures required by SFAS No. 148 in our Notes to Consolidated Financial Statements.

In January 2003, the FASB issued Interpretation No. 46, “Consolidation of Variable Interest Entities” (“FIN 46”) which changes the criteria by which one company includes another entity in its consolidated financial statements. FIN 46 requires a variable interest entity to be consolidated by a company if that company is subject to a majority of the risk of loss from the variable interest entity’s activities or entitled to receive a majority of the entity’s residual returns or both. The consolidation requirements of FIN 46 apply immediately to variable interest entities created after January 31, 2003, and apply in the first fiscal period beginning after June 15, 2003, for variable interest entities created prior to February 1, 2003. The Company has not entered into any transactions or other arrangements which it believes would be considered variable interest entities.

In May 2003, the FASB issued SFAS No. 150, “Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity.” SFAS No. 150 establishes standards for how an issuer classifies and measures certain financial instruments with characteristics of both liabilities and equity. It requires that an issuer classify a financial instrument that is within its scope as a liability (or an asset in some circumstances). Many of these instruments were previously classified as equity. The guidance in SFAS No. 150 is generally effective for all financial instruments entered into or modified after May 31, 2003, and otherwise is effective at the beginning of the first interim period beginning after June 15, 2003. The Company does not believe that the adoption of SFAS No. 150 will have a material impact on its consolidated financial statements.

2. Investments

For purposes of reporting, cash and cash equivalents include cash and interest-earning deposits or securities with original maturities of three months or less. At September 26, 2003, the Company has approximately $33.7 million in short-term investments and $2.0 million of long-term investments classified as available for sale. Such investments are currently held primarily in commercial paper, money market investments, and tax-exempt government securities. Net unrealized gains and losses on investments were not material at September 26, 2003. Additionally, the Company has $1.2 million of non-marketable equity investments, valued at the lower of cost or estimated fair value, which are included in long-term investments.

3. Long-Term Account Receivable

At September 26, 2003, the Company carried a long-term account receivable of approximately $6.2 million from a single client. The receivable relates to a major outsourcing contract and will be collected over the next three years.

4. Business Acquisitions

Businesses acquired through September 26, 2003, were accounted for in accordance with SFAS No. 141 (Business Combinations) and are included in the consolidated financial statements from the date of acquisition. Pro forma results of operations have not been presented because the effects of these acquisitions were not material on either an individual or aggregate basis.

Paragon Solutions, Inc.

On February 12, 2003, the Company acquired 100% of Paragon Solutions, Inc., a U.S. based provider of onshore and offshore software development services which is now part of the life sciences segment. The Company initially issued 600,500 unregistered shares of common stock and paid cash consideration of approximately $0.2 million to Paragon shareholders who elected cash payment. Since the acquisition, the Company has recovered 39,285 shares of its unregistered common stock from an escrow account to compensate it for certain undisclosed liabilities and expenses of Paragon. The Company also agreed to reserve an additional 49,540 shares of its common stock for issuance upon the exercise of options that were initially issued under Paragon’s stock incentive plans. Based upon a purchase price allocation analysis performed by an independent outside appraisal firm, intangible assets of approximately $1.0 million, related to contracts and agreements not to compete, and goodwill of approximately $8.3 million have been recorded. In connection with the acquisition, the Company immediately repaid $7.7 million of debt assumed from Paragon. Additionally, the Company acquired approximately $0.4 million of cash as part of the acquisition.

The following table summarizes the estimated fair values of assets acquired and liabilities assumed as of February 12, 2003 in connection with the Paragon acquisition (in thousands):

Accounts receivable	$	996
Other assets	1,212
Property and equipment, net	1,096
Goodwill	8,287
Intangible assets	990
Accrued liabilities	(1,543		)
Assumed debt including interest	(7,695		)
Net assets acquired	3,343
Value of stock issued	3,057
Cash consideration	$	286

Phyve Corporation

On February 20, 2003, the Company acquired the information security and connectivity software solution operations of Phyve Corporation for $1.4 million in cash. The following table summarizes the estimated fair values of assets acquired in connection with this acquisition (in thousands):

Intangible software	$	736
Property and equipment, net	229
Goodwill	387
Cash consideration	$	1,352

Coactive Systems Corporation

On May 30, 2003, the Company acquired 100% of Coactive Systems Corporation (Coactive) as an entry into the Business Process Outsourcing market. Coactive provides call center services and builds software customized for hospitals, health plans, and other healthcare organizations. The Company paid $0.6 million in cash to the shareholders of Coactive in the merger. In connection with the acquisition, the Company immediately repaid $1.5 million of debt assumed from Coactive.

The following table summarizes the estimated fair values of assets acquired and liabilities assumed as of May 30, 2003 in connection with the Coactive acquisition (in thousands):

Accounts receivable, net	$	201
Intangible software	441
Other assets	218
Property and equipment, net	106
Goodwill	1,413
Accrued liabilities	(226		)
Assumed debt including interest	(1,523		)
Cash consideration	$	630

Minority Interest Buy-out

On September 17, 2003, the Company acquired the 4.9% outstanding minority interest of FCG Management Services (FCGMS) from the University of Pennsylvania Health Systems (UPHS) for $1.86 million in cash. Since the minority interest had been subject to a put and call arrangement, the Company had been accounting for it as a sales incentive and amortizing it over the life of the UPHS contract term as a reduction of revenues in accordance with EITF 01-9, “Accounting for Consideration Given by a Vendor to a Customer”. Since the put and call arrangement was extinguished early by the agreement of the parties, the unamortized amount of $0.6 million was recorded as a reduction of revenue in the third quarter of 2003.

On September 26, 2003, the Company acquired the 15.0% outstanding minority interest of FCGMS from New York Presbyterian Hospital (NYPH). The transaction was accounted for as a purchase of minority interest in accordance with SFAS No. 141 “Business Combinations” in the third quarter of 2003. In consideration for NYPH’s 15.0% interest in FCGMS, the Company issued 1,000,000 unregistered shares of its common stock. Based upon a preliminary purchase price allocation, goodwill of approximately $1.8 million and intangible assets of $2.7 million have been recorded. Due to the recent closing date of the buyout, the purchase price allocations are tentative and subject to final purchase price valuation analysis.

As a result of the two transactions noted above, the Company now owns 100% of FCGMS.

5. Goodwill and Intangible Assets

In accordance with SFAS No. 142, the Company annually evaluates in the fourth fiscal quarter goodwill and intangible assets for impairment, as well as the related amortization periods for intangibles with definite lives, to determine whether adjustments to these amounts or estimated useful lives are required based on current events and circumstances. The evaluation is based on the Company’s projection of the future operating cash flows of the underlying assets combined with market valuation approaches. Significant estimates and assumptions were used in assessing the fair value of reporting units. These estimates and assumptions included future cash flows, growth rates, discount rates, weighted average cost of capital, and estimates of market valuation for each of the reporting units.

The changes in the net carrying amounts of goodwill for the nine months ended September 26, 2003 are as follows (in thousands):

	Healthcare		Life Sciences			Outsourcing			Total
Balance as of December 27, 2002	$	827	$	1,468		$	987		$	3,282
Acquired	—		10,193			430			10,623
Currency translation adjustment	—		(7		)	—			(7		)
Balance as of March 28, 2003	827		11,654			1,417			13,898
Acquired	—		—			1,370			1,370
Adjustment to purchase price allocation	—		(916		)	(200		)	(1,116		)
Currency translation adjustment	—		15			—			15
Balance as of June 27, 2003	827		10,753			2,587			14,167
Acquired	—		—			1,905			1,905
Adjustment to purchase price allocation	—		(990		)	—			(990		)
Currency translation adjustment	—		(6		)	—			(6		)
Balance as of September 26, 2003	$	827	$	9,757		$	4,492		$	15,076

As of September 26, 2003, the Company had the following acquired intangible assets recorded (in thousands):

Amortized Intangible Assets	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount		Amortization Period in Years
Software	$	736	$	(234	)	$	502	2
Customer based	3,841		(289		)	3,552		3 - 4
Non-compete agreements	400		(180		)	220		2 - 3
Software development	441		(44		)	397		2
Total	$	5,418	$	(747	)	$	4,671

The following table summarizes the estimated annual pretax amortization expense for these assets (in thousands):

Fiscal Year
2003	$	1,080
2004	1,697
2005	1,127
2006	884
2007	540
Total	$	5,328

6. Restructuring, Severance, and Impairment Costs

In the second quarter of 2002, the Company incurred a restructuring charge of $7.8 million consisting of $4.0 million in severance for the reduction of staff and $3.8 million in facility costs due to facility downsizing. At September 26, 2003, there was a balance of $4.9 million which primarily relates to vacated leases remaining from this and previous restructurings. The restructuring was accounted for in accordance with EITF 94-3 and SAB 100.

In the second quarter of 2003, the Company incurred a restructuring charge of $3.9 million consisting of $0.7 million in severance for the reduction of staff and $3.2 million in facility costs and fixed asset write-downs due to facility downsizing. At September 26, 2003, there was a balance of $1.7 million of accrued liabilities which primarily relates to vacated leases remaining from this restructuring. Due to these facilities being located in the same premises of prior vacated facilities and the interdependency of subleasing one or more areas, the separate calculation of what portion of the charge relates to newly versus previously vacated space is subjective, and therefore not presented. Payments on lease obligations are scheduled to continue until 2008. Market conditions and the ability to sublease these properties may affect the ultimate charge related to the lease obligations. Any potential recovery or additional charge may affect amounts reported in future periods.

In the third quarter of 2003, the Company incurred a restructuring charge of $4.2 million consisting of $3.6 million in severance for the reduction of staff and $0.6 million in facility costs and fixed asset write-downs due to facility downsizing. The $3.6 million severance charge represents 77 employees terminated during the quarter ended September 26, 2003. The unpaid portion in the amount of $1.1 million relating to this charge will be paid in the fourth quarter of 2003. The facility costs and fixed asset write-down of $0.6 million includes a charge for newly vacated facilities. Restructuring charges in 2003 have been accounted for in accordance with SFAS 146.

The restructuring liability for the nine months ended September 26, 2003 is summarized as follows (in thousands):

	Employee Related Costs			Facilities/Other Related Costs			Total
Reserve balance at December 27, 2002	$	1,093		$	6,485		$	7,578
Amounts paid, net of adjustments	(4,296		)	(3,191		)	(7,487		)
Restructuring charge	4,302			3,791			8,093
Reserve balance at September 26, 2003	$	1,099		$	7,085		$	8,184

7. Comprehensive Income (Loss)

Comprehensive income (loss), net of taxes, for the three months and nine months ended September 26, 2003 and September 27, 2002 is as follows (in thousands):

	Three Months Ended					Nine Months Ended
	September 26, 2003			September 27, 2002		September 26, 2003			September 27, 2002
Net income (loss)	$	(4,547	)	$	1,911	$	(9,993	)	$	62
Foreign currency translation adjustment, net of tax	(82		)	188		23			198
Unrealized gain (loss) on investments	6			9		42			(16		)
Comprehensive income (loss)	$	(4,623	)	$	2,108	$	(9,928	)	$	244

8. Cumulative Effect of Change in Accounting Principle

Effective December 28, 2002, the Company adopted EITF 00-21 “Accounting for Revenue Arrangements with Multiple Deliverables,” which addresses how to account for arrangements that involve the delivery or performance of multiple products, services, and/or rights to use assets. Revenue arrangements with multiple deliverables are divided into separate units of accounting if the deliverables in the arrangement meet the following criteria: (1) the delivered item has value to the customer on a standalone basis; (2) there is objective and reliable evidence of the fair value of undelivered items; and (3) delivery of any undelivered item is probable. Arrangement consideration should be allocated among the separate units of accounting based on their relative fair values, with the amount allocated to the delivered item being limited to the amount that is not contingent on the delivery of additional items or meeting other specified performance conditions. The new standard is required to be adopted for all new applicable revenue arrangements no later than the third quarter of 2003. Early adoption is permitted and the Company adopted the new standard as of the beginning of the first quarter of 2003. In addition, the Company has elected to apply the new standard to all existing outsourcing arrangements impacted by EITF 00-21 and record to earnings the resulting cumulative effect as a change in accounting principle. The adoption of EITF 00-21 resulted in a non-cash charge, net of tax, of $2.6 million, or $0.11 per share, in the first quarter of 2003. At September 26, 2003, the per share charge equates to $0.10 due to the increase in the number of shares outstanding.

The following table illustrates the effect on net income (loss) and income (loss) per share as if the change in accounting principle had been adopted in prior periods (in thousands, except per share data):

	Three Months Ended						Nine Months Ended
	September 26, 2003			September 27, 2002			September 26, 2003			September 27, 2002
Income (loss) before cumulative effect, as reported	$	(4,547	)	$	1,911		$	(7,396	)	$	62
Pro forma effect of change in accounting principle, net of tax	—			(50		)	—			(1,059		)
Pro forma net income (loss)	$	(4,547	)	$	1,861		$	(7,396	)	$	(997	)

Basic & diluted net income (loss) per share
Income (loss) before cumulative effect – as reported	$	(0.18	)	$	0.08		$	(0.30	)	$	0.00
Pro forma effect of change in accounting principle, net of tax	—			$	0.00		—			$	(0.04	)
Pro forma net income (loss) per share	$	(0.18	)	$	0.08		$	(0.30	)	$	(0.04	)

9. Disclosure of Segment Information

The Company currently has three reportable operating segments: healthcare (which is the delivery of consulting and systems integration (“CSI”) services to health delivery, health plan, and government clients), life sciences (which is the delivery of CSI services to pharmaceutical and other life sciences clients), and outsourcing (which is the delivery of information technology and business process outsourcing services to clients). The Company’s segments are managed on an integrated basis in order to serve clients by assembling multi-disciplinary teams, which provide comprehensive services. The amount of revenues attributed to each segment is accounted for by splitting the revenues on each client engagement based upon the hourly rates charged to the client for the services of each segment. Costs are not transferred across segments.

The Company evaluates its segments’ performance based on revenues and operating income. Selling and general and administrative expenses (including corporate functions, occupancy related costs, depreciation, professional development, recruiting, and marketing), to some extent, are managed at the corporate level and allocated to each operating segment based on either net revenues, actual usage, or other reasonable allocation methods. Total assets have not been disclosed by segment as the allocation of assets by segment is not practical.

The following segment information is for the three month and nine month periods ended September 26, 2003 and September 27, 2002 (in thousands):

For the three months ended September 26, 2003:

	Healthcare		Life Sciences			Outsourcing			Other			Totals
Revenues before reimbursements	$	28,667	$	12,162		$	25,020		$	—		$	65,849
Reimbursements	3,323		336			401			—			4,060
Total revenues	31,990		12,498			25,421			—			69,909
Cost of services before reimbursable expenses	16,995		8,597			21,117			—			46,709
Reimbursable expenses	3,323		336			401			—			4,060
Total cost of services	20,318		8,933			21,518			—			50,769
Gross profit	11,672		3,565			3,903			—			19,140
Selling expenses	3,736		2,387			389			190			6,702
General & administrative expenses	6,213		5,363			3,576			174			15,326
Restructuring, severance, and impairment costs	634		2,295			—			1,250			4,179
Income (loss) from operations	$	1,089	$	(6,480	)	$	(62	)	$	(1,614	)	$	(7,067	)

For the three months ended September 27, 2002:

	Healthcare		Life Sciences		Outsourcing		Other			Totals
Revenues before reimbursements	$	26,699	$	16,382	$	26,525	$	—		$	69,606
Reimbursements	3,027		414		46		—			3,487
Total revenues	29,726		16,796		26,571		—			73,093
Cost of services before reimbursable expenses	15,237		8,847		21,678		—			45,762
Reimbursable expenses	3,027		414		46		—			3,487
Total cost of services	18,264		9,261		21,724		—			49,249
Gross profit	11,462		7,535		4,847		—			23,844
Selling expenses	3,735		2,377		919		48			7,079
General & administrative expenses	5,955		4,703		2,587		226			13,471
Restructuring, severance, and impairment costs	—		—		—		—			—
Income (loss) from operations	$	1,772	$	455	$	1,341	$	(274	)	$	3,294

For the nine months ended September 26, 2003:

	Healthcare		Life Sciences			Outsourcing			Other			Totals
Revenues before reimbursements	$	86,554	$	45,135		$	75,600		$	—		$	207,289
Reimbursements	9,490		1,069			1,166			—			11,725
Total revenues	96,044		46,204			76,766			—			219,014
Cost of services before reimbursable expenses	50,611		27,802			64,586			—			142,999
Reimbursable expenses	9,490		1,069			1,166			—			11,725
Total cost of services	60,101		28,871			65,752			—			154,724
Gross profit	35,943		17,333			11,014			—			64,290
Selling expenses	12,453		6,975			1,589			653			21,670
General & administrative expenses	19,170		16,521			9,573			1,237			46,501
Restructuring, severance, and impairment costs	599		6,278			—			1,216			8,093
Income (loss) from operations	$	3,721	$	(12,441	)	$	(148	)	$	(3,106	)	$	(11,974	)

For the nine months ended September 27, 2002:

	Healthcare		Life Sciences			Outsourcing		Other			Totals
Revenues before reimbursements	$	85,034	$	51,914		$	62,133	$	—		$	199,081
Reimbursements	9,735		1,412			154		—			11,301
Total revenues	94,769		53,326			62,287		—			210,382
Cost of services before reimbursable expenses	48,611		29,378			49,655		—			127,644
Reimbursable expenses	9,735		1,412			154		—			11,301
Total cost of services	58,346		30,790			49,809		—			138,945
Gross profit	36,423		22,536			12,478		—			71,437
Selling expenses	10,214		6,949			2,958		791			20,912
General & administrative expenses	19,678		14,643			7,237		1,395			42,953
Restructuring, severance, and impairment costs	1,837		5,866			—		115			7,818
Income (loss) from operations	$	4,694	$	(4,922	)	$	2,283	$	(2,301	)	$	(246	)

Detail of Outsourcing Revenues:

Outsourcing revenues before reimbursements include revenues related to a major subcontractor on several projects. The breakdown of revenue in outsourcing is as follows (in thousands):

	Three Months Ended				Nine Months Ended
	September 26, 2003		September 27, 2002		September 26, 2003		September 27, 2002
Internally generated revenues	$	19,475	$	20,109	$	59,379	$	51,209
Subcontractor revenues	5,545		6,416		16,221		10,924
Revenues before reimbursements	$	25,020	$	26,525	$	75,600	$	62,133

10. Line of Credit

The Company has a revolving line of credit, under which it is allowed to borrow up to $7.0 million at an interest rate of the prevailing prime rate with an expiration of May 1, 2004. There was no outstanding balance under the line of credit at September 26, 2003. Due to a net loss at September 26, 2003, the Company is out of compliance with certain bank covenants contained in the line of credit agreement. However, the Company received a waiver for such non-compliance and is renegotiating the line of credit agreement to implement less restrictive covenants. While the Company believes it can successfully renegotiate its line of credit, there is no assurance that this will be accomplished.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

THE FOLLOWING MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS CONTAINS FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. SUCH FORWARD-LOOKING STATEMENTS INVOLVE RISKS AND UNCERTAINTIES, INCLUDING THOSE SET FORTH HEREIN UNDER THE CAPTION “RISKS RELATING TO OUR BUSINESS,” AND OTHER REPORTS WE FILE WITH THE SECURITIES AND EXCHANGE COMMISSION. OUR ACTUAL RESULTS COULD DIFFER MATERIALLY FROM THOSE ANTICIPATED IN THESE FORWARD-LOOKING STATEMENTS.

Overview

We provide services primarily to providers, payors, government agencies, pharmaceutical, biogenetic, and other healthcare organizations in North America, Europe, and Asia. We generate substantially all of our revenues from fees for professional services and information technology outsourcing services. We typically bill for our services on an hourly, fixed-fee, or monthly fixed-fee basis as specified by the agreement with a particular client. In our consulting and systems integration businesses (“CSI”), the healthcare and life sciences business units, we establish either standard or target hourly rates for each level of consultant based on several factors, including industry and assignment-related experience, technical expertise, skills, and knowledge. For services billed on an hourly basis, fees are determined by multiplying the amount of time expended on each assignment by the project hourly rate for the consultant(s) assigned to the engagement. Fixed fees, including outsourcing fees, are established on a per-assignment or monthly basis and are based on several factors such as the size, scope, complexity and duration of an assignment, the number of our employees required to complete the assignment, and the volume of transactions or interactions. Actual hourly or fixed fees for an assignment may vary from the standard, target, or historical rates that we have charged. Revenues are generally recognized related to the level of services performed based upon the amount of time completed on each assignment versus the projected number of hours required to complete such assignment, the amount of cost incurred on the assignment versus the estimated total cost to complete the assignment, or on a straight-line basis over the period of performance of service. Provisions are made for estimated uncollectible amounts based on our historical experience. We may obtain payment in advance of providing services. These advances are recorded as customer advances and reflected as a liability on our balance sheet.

Out-of-pocket expenses billed and reimbursed by clients are included in total revenues, and then deducted to determine net revenues. For purposes of analysis, all percentages in this discussion are stated as a percentage of net revenues, since we believe that this is the more relevant measure of our business.

Cost of services primarily consists of the salaries, bonuses, and related benefits of client-serving consultants and outsourcing associates, and subcontractor expenses. Selling expenses primarily consist of the salaries, benefits, travel, and other costs of our sales force, as well as marketing and market research expenses. General and administrative expenses primarily consist of the costs attributable to the support of our client-serving professionals, such as: non-billable travel; office space occupancy; information systems; salaries and expenses for executive management, financial accounting and administrative personnel; expenses for firm and business unit governance meetings; recruiting fees; professional development and training; and legal and other professional services. As associate related costs are relatively fixed in the short term, variations in our revenues and operating results in our CSI business can occur as a result of variations in billing margins and utilization rates of our billable associates.

Our most significant expenses are our human resource and related salary and benefit expenses. As of September 26, 2003, approximately 1,044 of our employees are billable consultants. Another 606 employees are part of our firm’s outsourcing business. The salaries and benefits of such billable

consultants and outsourcing related employees are recognized in our cost of services. Most non-billable employee salaries and benefits are recognized as a component of either selling or general and administrative expenses. Approximately 20.6% of our workforce, or 427 employees, are classified as non-billable. Our cost of services as a percentage of revenues is directly related to several factors, including, but not limited to, our consultant utilization, which is the ratio of total billable hours to available hours in a given period, the amount and timing of cost incurred, our ability to control costs on our outsourcing projects, the billed rate on time and material contracts, and the estimated cost to complete our non-outsourcing fixed price contracts. We evaluate our non-outsourcing fixed price contracts on a monthly basis by estimating the cost to complete the assignment. We then recognize revenues to achieve a constant margin over the remaining term of the engagement. We have changed our accounting for outsourcing contracts with the adoption of EITF 00-21, “Accounting for Revenue Arrangements with Multiple Deliverables,” in the first quarter of fiscal year 2003. Under our outsourcing contracts, a significant portion of our revenues are fixed and allocated over the contract on a straight-line basis, as we are required to provide a specified level of services subject to certain performance measurements. Also, certain revenues may fluctuate under the contracts based on the volume of transactions we process or other measurements of service provided. If we incur higher costs to provide the required services or receive less revenue due to reduced transaction volumes or penalties associated with service level failures, our gross profit can be negatively impacted.

In our CSI business, we manage consultant utilization by monitoring assignment requirements and timetables, available and required skills, and available consultant hours per week and per month. Differences in personnel utilization rates can result from variations in the amount of non-billed time, which has historically consisted of training time, vacation time, time lost to illness and inclement weather, and unassigned time. Non-billed time also includes time devoted to other necessary and productive activities such as sales support and interviewing prospective employees. Unassigned time results from differences in the timing of the completion of an existing assignment and the beginning of a new assignment. In order to reduce and limit unassigned time, we actively manage personnel utilization by monitoring and projecting estimated engagement start and completion dates and matching consultant availability with current and projected client requirements. The number of consultants staffed on an assignment will vary according to the size, complexity, duration, and demands of the assignment. Assignment terminations, completions, inclement weather, and scheduling delays may result in periods in which consultants are not optimally utilized. An unanticipated termination of a significant assignment or an overall lengthening of the sales cycle could result in a higher than expected number of unassigned consultants and could cause us to experience lower margins. In addition, expansion into new markets and the hiring of consultants in advance of client assignments have resulted and may continue to result in periods of lower consultant utilization.

In response to competition and continued pricing and rate pressures, we have recently implemented a global sourcing strategy into our business operations, which includes the deployment of offshore resources as well as resources that perform services remote from the client site. We expect this strategy to result in improved cost of services through a combination of lower cost attributable to offshore resources and higher leverage of resources that perform services offsite. To the extent we pass through reduced costs to our clients, the global sourcing strategy may result in lower revenues on a per engagement basis. However, we expect to offset this potential revenue impact with improved competitive positioning in our markets. Several of our competitors employ a global sourcing strategy to provide software development and other information technology services to their clients, while at the same time reducing their cost structure and improving the quality of services they provide. If we are unable to realize the perceived cost benefits of our recently implemented global sourcing strategy or if we are unable to receive high quality services from foreign employees or subcontractors, our business may be adversely impacted and we may not be able to compete effectively.

Results of Operations for the Three Months Ended September 26, 2003 and September 27, 2002

Revenues. Our net revenues decreased to $65.8 million for the quarter ended September 26, 2003, a decrease of 5.4% from $69.6 million for the quarter ended September 27, 2002. Our total revenues decreased to $69.9 million for the quarter ended September 26, 2003, a decrease of 4.4% from $73.1 million for the quarter ended September 27, 2002. The decrease was primarily due to a significant decline in life sciences business unit revenues. Life sciences business unit revenue declined by $4.2 million and the decline would have been $7.0 million excluding the acquisition of Paragon Solutions, Inc. Additionally, our outsourcing business unit revenue declined slightly due to lower subcontractor pass throughs. Although our healthcare business unit revenue increased, we have some contracts in the health plan sector of that business which will be concluding over the remainder of 2003. If we are unable to compensate for the revenue loss of these contracts with new or follow-on engagements, we may experience a decline in revenues in the healthcare business unit.

Cost of Services. Cost of services before reimbursable expenses increased to $46.7 million for the quarter ended September 26, 2003, an increase of 2.1% from $45.8 million for the quarter ended September 27, 2002. The increase is primarily due to the costs of services from our recent acquisitions, partially offset by a reduction in staff in our life sciences business unit.

Gross Profit. Gross profit decreased to $19.1 million for the quarter ended September 26, 2003, a decrease of 19.7% from $23.8 million for the quarter ended September 27, 2002. The decrease is primarily due to the major revenue decline in our life sciences business unit, as we did not reduce costs as quickly as the decline in our revenues. Gross profit, as a percentage of net revenues, decreased from 34.3% for the quarter ended September 27, 2002 to 29.1% for the quarter ended September 26, 2003, due to the factors discussed above.

Selling Expenses. Selling expenses decreased to $6.7 million for the quarter ended September 26, 2003, a decrease of 5.3% from $7.1 million for the quarter ended September 27, 2002. The decrease is primarily due to recent reductions in our sales force. Selling expenses, as a percentage of net revenues, remained constant at 10.2% for the quarter ended September 26, 2003 compared to the quarter ended September 27, 2002.

General and Administrative Expenses. General and administrative expenses increased to $15.3 million for the quarter ended September 26, 2003, an increase of 13.8% from $13.5 million for the quarter ended September 27, 2002. The increase was primarily due to general and administrative expenses from our recently acquired companies, and investments in software product development in life sciences and in the Patient Safety Institute and related technologies. General and administrative expenses, as a percentage of net revenues, increased from 19.4% for the quarter ended September 27, 2002 to 23.3% for the quarter ended September 26, 2003. Our general and administrative expenses declined by $1.3 million compared to the quarter ended June 27, 2003. We are planning to continue our significant cost reduction efforts and we expect that our general and administrative expenses will decline during the next several quarters.

Restructuring, Severance, and Impairment Costs. Restructuring, severance, and impairment costs were $4.2 million for the three months ended September 26, 2003 compared to zero for the three months ended September 27, 2002. Restructuring, severance, and impairment costs for the three months ended September 26, 2003 included approximately $3.6 million of severance costs related to staff reductions and $0.6 million for facility downsizing and fixed asset write-downs. We expect to incur additional restructuring charges in the fourth quarter of fiscal year 2003 as we reduce additional staff and general and administrative expenses from our healthcare and life sciences business units.

Interest Income, Net. Interest income, net of interest expenses, remained constant at $0.2 million for the quarter ended September 26, 2003 compared to the quarter ended September 27, 2002. Interest income, net of interest expense, as a percentage of net revenues, increased from 0.3% for the quarter ended September 27, 2002 to 0.4% for the quarter ended September 26, 2003.

Other Expenses, Net. Other expense remained constant at $0.2 million for the quarter ended September 26, 2003 compared to the quarter ended September 27, 2002.

Income Taxes. The benefit for income taxes was 35% for the quarter ended September 26, 2003, compared to a provision rate of 42% in the quarter ended September 27, 2002. The benefit rate is lower than the previous provision rate due to the existence of certain non-deductible expenses.

Results of Operations for the Nine Months Ended September 26, 2003 and September 27, 2002

Revenues. Our net revenues increased to $207.3 million for the nine months ended September 26, 2003, an increase of 4.1% from $199.1 million for the nine months ended September 27, 2002. Total revenues increased to $219.0 million for the nine months ended September 26, 2003, an increase of 4.1% from $210.4 million for the nine months ended September 27, 2002. The increases were primarily due to revenues from our acquisitions and from two outsourcing contracts that began mid-2002. These increases were partially offset by the significant decline in our life sciences business unit revenues (excluding revenues from our acquisition of Paragon Solutions, Inc.). We completed a significant client engagement in March 2003 in our life sciences business unit and have been unable to replace that revenue with new engagements. If we do not obtain new engagements and/or additional work from this or other clients, we could see a further decline in revenues in our life sciences business unit. Additionally, we have some contracts in the health plan sector of our healthcare business unit which will be concluding over the remainder of 2003. If we are unable to replace these contracts with new or follow-on engagements, we could see a decline in revenues in our healthcare business unit as well.

Cost of Services. Cost of services before reimbursable expenses increased to $143.0 million for the nine months ended September 26, 2003, an increase of 12.0% from $127.6 million for the nine months ended September 27, 2002. The increase is primarily due to the costs of services of the outsourcing engagements that began in mid-2002 and costs of services from our recent acquisitions, partially offset by a reduction in staff in our life sciences business unit.

Gross Profit. Gross profit decreased to $64.3 million for the nine months ended September 26, 2003, a decrease of 10.0% from $71.4 million for the nine months ended September 27, 2002 primarily due to the decline in revenues, as well as the change in our revenue mix from life sciences revenues to outsourcing business unit revenues, which are generally at a lower gross profit. Additionally, gross profit in our life sciences business unit declined as we did not reduce costs as quickly as the decline in our revenues. Gross profit, as a percentage of net revenues, decreased to 31.0% for the nine months ended September 26, 2003 from 35.9% for the nine months ended September 27, 2002, due to the factors discussed above and lower gross profit percentages on our outsourcing contracts compared to the prior year. This lower gross profit in our outsourcing business unit is related to the higher proportion of subcontractors in our more recent contracts, and cost overruns on certain outsourcing contracts in the first quarter of fiscal year 2003.

Selling Expenses. Selling expenses increased to $21.7 million for the nine months ended September 26, 2003, an increase of 3.6% from $20.9 million for the nine months ended September 27, 2002. The increase is primarily due to selling costs added by the acquisition of Paragon Solutions, Inc. and an increase in salespeople for our healthcare business unit. Selling expenses, as a percentage of net revenues, remained constant at 10.5% for the nine months ended September 26, 2003 compared to the nine months ended September 27, 2002.

General and Administrative Expenses. General and administrative expenses increased to $46.5 million for the nine months ended September 26, 2003, an increase of 8.3% from $43.0 million for the nine months ended September 27, 2002. The increase is primarily due to costs from our recently acquired companies and investments we are making in software product development in our life sciences business unit, the Patient Safety Institute and related technologies. General and administrative expenses, as a percentage of net revenues, increased from 21.6% for the nine months ended September 27, 2002 to 22.4% for the nine months ended September 26, 2003.

Restructuring, Severance, and Impairment Costs. Restructuring, severance, and impairment costs were $8.1 million for the nine months ended September 26, 2003 compared to $7.8 million for the nine months ended September 27, 2002. Restructuring, severance and impairment costs for the nine months ended September 26, 2003 included approximately $4.3 million of severance costs related to staff reductions and approximately $3.8 million for facility downsizing and fixed asset write-downs. Restructuring, severance, and impairment costs for the nine months ended September 27, 2002 included approximately $4.0 million of severance costs related to staff reductions and approximately $3.8 million for facility downsizing. We expect to incur additional severance costs in the fourth quarter of fiscal year 2003 as we reduce additional staff and general and administrative expense from our healthcare and life sciences business units.

Interest Income, Net. Interest income, net of interest expenses, increased to $0.8 million for the nine months ended September 26, 2003 from $0.7 million for the nine months ended September 27, 2002. Interest income, net of interest expenses, as a percentage of net revenues increased from 0.3% for the nine months ended September 27, 2002 to 0.4% for the nine months ended September 26, 2003.

Other Expenses, Net. Other expense decreased to $0.2 million for the nine months ended September 26, 2003 from $0.3 million for the nine months ended September 27, 2002. The decrease is primarily due to a reduction in minority interest expense.

Income Taxes. The benefit for income taxes was 35% for the nine months ended September 26, 2003 compared to a provision rate of 42% for the nine months ended September 27, 2002. The benefit rate is lower than the provision rate due to the existence of certain non-deductible expenses.

Cumulative Effect of Change in Accounting Principle. In November 2002, the EITF reached a consensus on Issue 00-21, titled “Accounting for Revenue Arrangements with Multiple Deliverables,” which addresses how to account for arrangements that involve the delivery or performance of multiple products, services, and/or rights to use assets. The new standard was required to be adopted for applicable revenue arrangements no later than the third quarter of 2003. Early adoption was permitted, and we adopted the new standard as of the beginning of 2003. In addition, we elected to apply the new standard to all existing outsourcing arrangements impacted by EITF 00-21 and recorded to earnings in the first quarter of 2003 the resulting cumulative effect as a change in accounting principle. We recorded a non-cash charge, net of tax, of $2.6 million, or $0.11 per share, in the first quarter of 2003. At September 26, 2003, the per share charge equates to $0.10 due to the increase in the number of shares outstanding.

Liquidity and Capital Resources

During the nine months ended September 26, 2003, we generated cash flow from operations of $4.5 million. During the nine months ended September 26, 2003, we used approximately $11.2 million to acquire three companies (see Note 4 of the Notes to Consolidated Financial Statements) and $4.2 million of cash to purchase property and equipment, including computer and related equipment, and office furniture. We also used $1.86 million during the quarter ended September 26, 2003 to purchase the 4.9%

minority interest that the University of Pennsylvania Health System had in FCG Management Services, LLC. At September 26, 2003, we had cash and investments available for sale of $58.5 million compared to $67.3 million at December 27, 2002.

We have a revolving line of credit, under which we are allowed to borrow up to $7.0 million at an interest rate of the prevailing prime rate with an expiration of May 1, 2004. There was no outstanding balance under the line of credit at September 26, 2003. Due to our net loss at September 26, 2003, we are out of compliance with certain bank covenants contained in the line of credit agreement. However, we received a waiver for such non-compliance and we are renegotiating our line of credit agreement to implement less restrictive covenants. While we believe we can renegotiate the line of credit agreement, there is no assurance that this will be successfully accomplished.

Management believes that our existing cash and investments, together with funds generated from operations, will be sufficient to meet operating requirements for at least the next twelve months. Our cash and investments are available for capital expenditures (which are projected at approximately $6.0 million for 2003, $4.2 million of which was spent during the nine months ended September 26, 2003), strategic investments, mergers and acquisitions, and other potential large-scale cash needs that may arise, including $2.4 million in cash that is expected to be spent on or about January 2004 to purchase the remaining 47.65% minority interest in FCG Infrastructure Services (formerly Codigent Solutions Group, Inc.) that we do not already own.

On October 1, 2003, we entered into a letter agreement with each of Northern Westchester Hospital Center, Lawrence Hospital Center and Phelps Memorial Hospital Center obligating us to reimburse such hospitals for their interest expense incurred on third party lines of credit if our system implementation at the hospitals results in an increase in the hospitals’ accounts receivable days outstanding during a 120-day period after the completion of the system implementation. Under these letter agreements, we are only obligated to reimburse actual interest charges (which cannot exceed the prime rate plus 2%) on principal amounts borrowed by the hospitals, up to a maximum principal amount of approximately $6.7 million in the aggregate, for a 120-day period. We do not currently expect to incur any expense in connection with these letter agreements until early 2005, if at all.

On October 1, 2003, we also entered into an unsecured loan agreement with White Plains Hospital Center requiring us to provide interest free financing of up to $4.08 million if our system implementation at the hospital results in an increase in the hospital’s accounts receivable balance or days outstanding during a 150-day period following the completion of the system implementation. Any amounts borrowed during this 150-day period are payable 90 days after the borrowing date. We do not currently expect to make any loans under this agreement until early 2005, if at all. Since our loans are unsecured, we cannot guarantee that the hospital will repay our loans on a timely basis, if at all. If our loans are not repaid or repaid in a timely manner, our financial condition would be impacted negatively.

The following table summarizes our contractual and other commitments (in thousands):

	Payments Due by Period
Contractual Obligations	Total		Less than 1 Year		1 - 3 Years		4 -5 Years		After 5 Years
Operating Leases	$	24,130	$	5,597	$	9,532	$	6,463	$	2,538
Purchase Obligations	774		310		464		—		—
	$	24,904	$	5,907	$	9,996	$	6,463	$	2,538

Critical Accounting Policies and Estimates

The foregoing discussion and analysis of our financial condition and results of operations is based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates, including those related to revenue recognition, cost to complete client engagements, valuation of goodwill and long-lived and intangible assets, accrued liabilities, income taxes, restructuring costs, idle facilities, litigation and disputes, and the allowance for doubtful accounts. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Our actual results may differ from our estimates and we do not assume any obligation to update any forward-looking information.

We believe the following critical accounting policies reflect our more significant assumptions and estimates used in the preparation of our consolidated financial statements.

Revenue Recognition and Unbilled Receivables

Revenues are derived primarily from consulting, systems integration, and information technology outsourcing services. Revenues are recognized on a time-and-materials, level-of-effort, percentage-of-completion, or straight-line basis. Before revenues are recognized, the following four criteria must be met: (a) persuasive evidence of an arrangement exists; (b) delivery has occurred or services rendered; (c) the fee is fixed and determinable; and (d) collectibility is reasonably assured. We determine if the fee is fixed and determinable and collectibility is reasonably assured based on our judgments regarding the nature of the fee charged for services rendered and products delivered and the collectibility of those fees. Arrangements range in length from less than one year to seven years. The longer-term arrangements are generally level-of-effort or fixed price arrangements.

Revenues from time-and-materials arrangements are generally recognized based upon contracted hourly billing rates as the work progresses. Revenues from level-of-effort arrangements are recognized based upon a fixed price for the level or resources provided. Revenues from fixed fee arrangements for consulting and systems integration work are generally recognized on a percentage-of-completion basis. We maintain, for each of our fixed fee contracts, estimates of total revenue and cost over the contract term. For purposes of periodic financial reporting on the fixed price consulting and system integration contracts, we accumulate total actual costs incurred to date under the contract. The ratio of those actual costs to our then-current estimate of total costs for the life of the contract is then applied to our then-current estimate of total revenues for the life of the contract to determine the portion of total estimated revenues that should be recognized. We follow this method because reasonably dependable estimates of the revenues and costs applicable to various stages of a contract can be made.

Revenues recognized on fixed price consulting and system integration contracts are subject to revisions as the contract progresses to completion. If we do not accurately estimate the resources required or the scope of the work to be performed, do not complete our projects within the planned periods of time, or do not satisfy our obligations under the contracts, then profit may be significantly and negatively affected or losses may need to be recognized. Revisions in our contract estimates are reflected in the period in which the determination is made that facts and circumstances dictate a change of estimate. Favorable changes in estimates result in additional revenues recognized, and unfavorable changes in estimates result in a reduction of recognized revenues. Provisions for estimated losses on individual contracts are made in the period in which the loss first becomes known. Some contracts include

incentives for achieving either schedule targets, cost targets, or other defined goals. Revenues from incentive type arrangements are recognized when it is probable they will be earned.

As of the beginning of fiscal year 2003, we adopted EITF 00-21, “Accounting for Revenue Arrangements with Multiple Deliverables,” which addresses how to account for arrangements that involve the delivery or performance of multiple products, services, and/or rights to use assets. Revenue arrangements with multiple deliverables are divided into separate units of accounting if the deliverables in the arrangement meet the following criteria: (1) the delivered item has value to the customer on a stand-alone basis; (2) there is objective and reliable evidence of the fair value of undelivered items; and (3) delivery of any undelivered item is probable. Arrangement consideration should be allocated among the separate units of accounting based on their relative fair values, with the amount allocated to the delivered item being limited to the amount that is not contingent on the delivery of additional items or meeting other specified performance conditions. We have created separate units of accounting on our existing outsourcing contracts based on the above criteria and will do so on our future contracts. Generally, we have separated certain elements of our initial contract stages, where processes are reengineered into a new operating environment, from the ongoing operations of the contract. The primary impact of the adoption of this standard is that our ongoing contract operations, which constitute the vast majority of the revenues from outsourcing contracts, will be recorded on a straight-line basis over the life of the contract instead of on a percentage-of-completion basis in proportion to costs incurred. In general, we will report lower margins on existing contracts in the early years of a contract and anticipate reporting increased margins in the later years of a contract; however, no assurances can be made in that regard. The new method will no longer be based on a consistent gross profit over the life of a contract. We will likely experience greater volatility of outsourcing earnings as contract revenues remain level and contract costs move up or down, or shift from one quarter to another.

As part of our on-going operations to provide services to our customers, incidental expenses, which are generally reimbursable under the terms of the contracts, are billed to customers. These expenses are recorded as both revenues and direct cost of services in accordance with the provisions of EITF 01-14, “Income Statement Characterization of Reimbursements Received for ‘Out-of-Pocket’ Expenses Incurred,” and include expenses such as airfare, mileage, hotel stays, out-of-town meals, and telecommunication charges.

Unbilled receivables represent revenues recognized for services performed that were not billed at the balance sheet date. The majority of these amounts are billed in the subsequent month. Unbillable amounts arising from contracts occur when revenues recognized exceed allowable billings in accordance with the contractual agreements. As of September 26, 2003, we had unbillable revenues included in current unbilled receivables of approximately $0.4 million, which were generally expected to be billed in the following quarter. In addition, we had long-term unbilled receivables at September 26, 2003, and September 27, 2002 of $6.2 million and $8.1 million, respectively, on a single major outsourcing contract with a term of seven years. The long-term receivable will be billed and collected over the remaining three years of the contract through contractual billings that will exceed the amounts to be earned as revenues.

Customer advances comprise payments from customers for which services have not yet been performed or prepayments against work in process. These unearned revenues are deferred and recognized as future contract costs are incurred and as contract services are rendered.

Allowance for Doubtful Accounts

We maintain an allowance for doubtful accounts for estimated losses resulting from the inability of our clients to make required payments. If the financial condition of our clients were to deteriorate, resulting in an impairment of their ability to make payments, additional allowances may be required. Management analyzes account receivables and historical bad debt, customer concentrations, credit

worthiness, past collection experience, current economic trends, and changes in our customer payment terms when evaluating the adequacy of doubtful accounts.

Deferred Income Taxes

We account for income taxes in accordance with SFAS No. 109, “Accounting for Income Taxes,” which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Our net deferred tax assets have historically consisted primarily of the tax benefit related to restructuring costs for facility closures, supplemental executive retirement plan contributions, and other accrued liabilities such as accrued vacation pay, which are not deductible for tax purposes until paid. During fiscal year 2003, we have generated additional deferred tax assets for net operating loss carryforwards resulting from the losses we are incurring, caused in part by the cumulative effect of our change in revenue recognition method on our outsourcing contracts. The Company uses significant estimates in the calculation of its income tax benefit by estimating that it will have sufficient future taxable income to realize its deferred tax assets in full and does not need to record a valuation allowance at this time. Based on our belief that it is more likely than not that future taxable income will be sufficient to realize the deferred tax assets, we have not recorded a valuation allowance against our deferred tax asset. However, there is no guarantee that our taxable income will be sufficient to realize such deferred tax assets, so we will continue to evaluate the potential need for a valuation allowance on an ongoing basis.

Goodwill and Intangible Assets

Under SFAS No 142, we no longer amortize our goodwill and are required to complete an annual impairment testing the fourth quarter of each year. We believe that the accounting assumptions and estimates related to the annual goodwill impairment testing are critical because these can change from period to period. The impairment test requires us to forecast our future cash flows, which involves significant judgment. Our operating results have been negatively impacted by the worldwide economic conditions. Accordingly, if our expectations of future operating results change, or if there are changes to other assumptions, our estimate of the fair value of our reporting units could change significantly resulting in a goodwill impairment charge, which could have a significant impact on our consolidated financial statements. As of September 26, 2003, we have $15.1 million of goodwill and $4.7 million of intangible assets recorded on our balance sheet (see Note 5 of the Notes to Consolidated Financial Statements).

Recent Accounting Pronouncements

See Note 1 of the Notes to the Consolidated Financial Statements for a discussion on recent accounting pronouncements.

Risks Relating to Our Business

Before deciding to invest in us or to maintain or increase your investment, you should carefully consider the risks described below, in addition to the other information contained in this report. The risks and uncertainties described below are not the only ones facing our company. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also affect our business operations. If any of these risks are realized, our business, financial condition or results of operations could be seriously harmed. In that event, the market price for our common stock could decline and you may lose all or part of your investment.

Many factors may cause our net revenues, operating results and cash flows to fluctuate and possibly decline.

Our net revenues, operating results, and cash flows may fluctuate significantly because of a number of factors, many of which are outside of our control. These factors may include:

• The loss of one or more significant clients in any of our business segments;

• The roll-off or completion of significant projects in any of our business segments;

• Fluctuations in market demand for our services, consultant hiring, and utilization;

• Delays or increased expenses in securing and completing client engagements;

• Timing and collection of fees and payments;

• Timing of new client engagements in any of our business segments;

• Increased competition and pricing pressures;

• Use of offsite and offshore resources on our engagements;

• The loss of key personnel and other employees;

• Changes in our, and our competitor’s, business strategy, pricing and billing policies;

• The timing of certain general and administrative expenses;

• Completing acquisitions and the costs of integrating acquired operations;

• Variability in the number of billable days in each quarter;

• The write-off of client billings;

• Return of fees for work deemed unsatisfactory by a client or claims or litigation resulting from the same;

• Entry into fixed price engagements and engagements where some fees are contingent upon the client realizing a certain return on investment for a project;

• Availability of foreign net operating losses and other credits against our earnings;

• International currency fluctuations;

• Ability to sublease vacant office space included in previous restructuring charges; and

• The fixed nature of a substantial portion of our expenses, particularly personnel and related costs, depreciation, office rent, and occupancy costs.

One or more of the foregoing factors may cause our operating expenses to be unexpectedly high during any given period. In addition, we bill certain of our services on a fixed-price basis, and any assignment delays or expenditures of time beyond that projected for the assignment could result in write-offs of client receivables (both unbilled and billed). Significant write-offs could materially adversely affect our business, financial condition, and results of operations. Our business also has significant collection risks. If we are unable to collect our receivables in a timely manner, our business and financial condition could also suffer. If these or any other variables or unknowns were to cause a shortfall in revenues or earnings or otherwise cause a failure to meet public market expectations, our business could be adversely affected.

Further, we adopted EITF 00-21 in the first quarter of 2003, which affects the way we recognize revenue on long-term outsourcing agreements. The adoption of EITF 00-21 results in separating our outsourcing contracts into multiple elements and separately accounting for each element, rather than accounting for all elements together as a group. As a result, we now recognize revenue from certain service elements of our outsourcing agreements on a straight-line basis over the life of the contract, rather than on a percentage of completion basis. Since we typically incur greater costs and expenses during the early phase of the service elements (which will now have straight-line revenue) than we do in the later years of those elements, we believe our net income will be less during the early stages of our outsourcing engagements. In addition, if we are unable to manage costs as planned in the later stages of an outsourcing engagement, our net income will likewise be negatively impacted. In general, income from our outsourcing contracts will be less stable in the future, since it will be more susceptible to changes in the mix of newer versus older contracts, and to the impact of cost fluctuations from quarter to quarter without a compensating change in revenue. If we fail to meet our public market expectations or otherwise experience a shortfall in our net income due to these fluctuations, our business could be adversely affected and the price of our stock may decline.

Finally, we reported net losses for the second quarter and third quarter of 2003, and we cannot assure you that we will achieve positive earnings in the future. If we are unable to achieve profitability on a quarterly or annual basis, the market price of our common stock could be adversely affected and our financial condition would suffer.

Our outsourcing engagements comprise a significant part of our revenues.

Our outsourcing agreements require that we invest significant amounts of time and resources in order to win the engagement, transition the client’s information technology department to our management, and complete the initial transformation of our client’s information technology functioning to provide improved service at a lower cost and meet agreed-upon service levels. Often, we recover this investment through payments over the life of the outsourcing agreement. If we are unable to achieve agreed-upon service levels or otherwise breach the terms of our outsourcing agreements, the clients may have rights to terminate our agreements for cause and we may be unable to recover our investments. Any failure by us to recover these investments may have a material adverse effect on our financial condition, results of operations, and price of our common stock.

Currently, we have seven active outsourcing relationships. Net revenues from such outsourcing relationships, as of the quarter ended September 26, 2003, represented approximately 39% of our consolidated net revenues. The substantial majority of these revenues are received from four large outsourcing accounts that have signed long term agreements with us. However, the loss of any of our outsourcing relationships would have a material impact on our business and results of operations. In each of these engagements, the clients have fully outsourced their information technology staff and functions to us. In all of our outsourcing relationships, we generally enter into additional agreements, including detailed service level agreements, which establish performance levels and standards for our services. If we fail to meet these performance levels or standards, our clients may receive monetary service level credits from us or, if we experience persistent failures, our clients may have a right to terminate the outsourcing contract for cause and have no obligation to pay us any termination fees. Our anticipated revenues from our outsourcing engagements could be significantly reduced if we are unable to satisfy our performance levels or standards. Additionally, our outsourcing contracts can be terminated at the convenience of our clients upon the payment of a termination fee.

Our outsourcing engagements typically require that we hire part or all of a client’s information technology personnel. We cannot assure you that we will be able to retain these individuals, and effectively hire additional personnel as needed to meet the obligations of our contract. Any failure by us to retain these individuals or otherwise satisfy our contractual obligations could have a material adverse

effect on the profitability of our outsourcing business and our reputation as an information technology services outsourcing provider.

Finally, we have publicly announced our intentions to expand our outsourcing business and perform our information technology outsourcing services for other potential clients. We anticipate expanding our outsourcing business to perform discrete information technology services for clients. The amount of time and resources required to win client engagements for our outsourcing business is significant, and we may not win the number or type of client engagements that we anticipate. If we fail to meet our objective to secure new outsourcing engagements, or fail to secure new outsourcing engagements on acceptable commercial terms, we will not experience the growth in this business unit that we have anticipated.

In May 2003, we completed the acquisition of a company that provides inbound and outbound call center services to the hospital and payer markets. The acquisition represents our entry into the business process outsourcing market (BPO). If we are unable to successfully integrate and leverage this acquisition in the BPO market, we may not be able to successfully execute our strategy in this area. Further, all acquisitions involve risks that could materially and adversely affect our business and operating results. Consequently, we may fail to meet public market expectations and the price of our common stock may decline.

The length of time required to engage a client and to complete an assignment may be unpredictable and could negatively impact our net revenues and operating results.

The timing of securing our client engagements and service fulfillment is difficult to predict with any degree of accuracy. Prior engagement cycles are not necessarily an indication of the timing of future client engagements or revenues. The length of time required to secure a new client engagement or complete an assignment often depends on factors outside our control, including:

• Existing information systems at the client site;

• Changes or the anticipation of changes in the regulatory environment affecting healthcare and pharmaceutical organizations;

• Changes in the management or ownership of the client;

• Budgetary cycles and constraints;

• Changes in the anticipated scope of engagements;

• Availability of personnel and other resources; and

• Consolidation in the healthcare and pharmaceutical industries.

Prior to client engagements, we typically spend a substantial amount of time and resources (1) identifying strategic or business issues facing the client, (2) defining engagement objectives, (3) gathering information, (4) preparing proposals, and (5) negotiating contracts. Our failure to procure an engagement after spending such time and resources could materially adversely affect our business, financial condition, and results of operations. We may also be required to hire new consultants before securing a client engagement. If clients defer committing to new assignments for any length of time or for any reason we could be required to maintain a significant number of under-utilized consultants which could adversely affect our operating results and financial condition during any given period. Further, our outsourcing business has very long sales and contract lead times, requiring us to spend a substantial amount of time and resources in attempting to secure each outsourcing engagement. We cannot predict whether the investment of time and resources will result in a new outsourcing engagement or, if the engagement is secured, that the engagement will be on terms favorable to us.

We could be negatively impacted if we fail to successfully integrate the businesses we acquire.

We have grown, in part, by acquiring complementary businesses that could enhance our capability to serve the healthcare and pharmaceutical industries. For example, in May 2002, we acquired a majority interest in Codigent Solutions Group, Inc. (now known as FCG Infrastructure Services, Inc.) and during the first half of 2003, we acquired Paragon Solutions, Inc., Coactive Systems Corporation, and certain assets of Phyve Corporation. All acquisitions involve risks that could materially and adversely affect our business and operating results. These risks include:

• Distracting management from our business;

• Losing key personnel and other employees;

• Losing clients;

• Costs, delays, and inefficiencies associated with integrating acquired operations and personnel;

• The impairment of acquired assets and goodwill; and

• Acquiring the contingent and other liabilities of the businesses we acquire

In addition, acquired businesses may not enhance our services, provide us with increased client opportunities, or result in the growth that we anticipate. Furthermore, integrating acquired operations is a complex, time-consuming, and expensive process. Combining acquired operations with us may result in lower overall operating margins, greater stock price volatility, and quarterly earnings fluctuations. Cultural incompatibilities, career uncertainties, and other factors associated with such acquisitions may also result in the loss of employees and clients. Failing to acquire and successfully integrate complementary practices, or failing to achieve the business synergies that we anticipate, could materially adversely affect our business and results of operations.

We may be negatively impacted if investments in products and emerging service lines are unsuccessful.

We have publicly announced our strategy to increase our investment in product development, particularly in our life sciences business unit, in addition to continuing our investments in emerging service lines. We typically do not capitalize the cost of our product development activities and do not anticipate capitalizing expected investments. As a result, our financial results may be adversely impacted by such increased investment in the short term. If such product development activities or investment in our emerging service lines do not result in relevant offerings, we will not achieve desired levels of return on these investments. As a result, our business and results of operations could be adversely affected.

If we are unable to generate additional revenue from our existing clients, our business may be negatively affected.

Our success depends, to a significant extent, on obtaining additional engagements from our existing clients. A substantial portion of our revenues is derived from additional services provided to our existing clients. The loss of a small number of clients may result in a material decline in revenues and cause us to fail to meet public market expectations of our financial performance and operating results. If we fail to generate additional revenues from our existing clients it may materially adversely affect our business and financial condition.

If we fail to meet client expectations in the performance of our services, our business could suffer.

Our services often involve assessing and/or implementing complex information systems and software, which are critical to our clients’ operations. Our failure to meet client expectations in the performance of our services, including the quality, cost and timeliness of our services, may damage our

reputation in the healthcare and pharmaceutical industries and adversely affect our ability to attract and retain clients. If a client is not satisfied with our services, we will generally spend additional human and other resources at our own expense to ensure client satisfaction. Such expenditures will typically result in a lower margin on such engagements and could materially adversely affect our business, financial condition, and results of operations.

Further, in the course of providing our services, we will often recommend the use of software and hardware products. These products may not perform as expected or contain defects. If this occurs, our reputation could be damaged and we could be subject to liability. We attempt contractually to limit our exposure to potential liability claims; however, such limitations may not be effective. A successful liability claim brought against us may adversely affect our reputation in the healthcare and pharmaceutical industries and could have a material adverse effect on our business or financial condition. Although we maintain professional liability insurance, such insurance may not provide adequate coverage for successful claims against us.

We may be unable to attract and retain a sufficient number of qualified employees.

Our business is labor-intensive and requires highly skilled employees. Most of our consultants possess extensive expertise in the healthcare, insurance, pharmaceutical, information technology and consulting fields. To serve a growing client base, we must continue to recruit and retain qualified personnel with expertise in each of these areas. Competition for such personnel is intense and we compete for such personnel with management consulting firms, healthcare and pharmaceutical organizations, software firms, and other businesses. Many of these entities have substantially greater financial and other resources than we do, or can offer more attractive compensation packages to candidates, including salary, bonuses, stock, and stock options. If we are unable to recruit and retain a sufficient number of qualified personnel to serve existing and new clients, our ability to expand our client base or services could be impaired and our business would suffer.

The loss of our key client service employees and executive officers could negatively affect us

Our performance depends on the continued service of our executive officers, senior managers, and key employees. In particular, we depend on such persons to secure new clients and engagements and to manage our business and affairs. The loss of such persons could result in the disruption of our business and could have a material adverse effect on our business and results of operations. We have not entered into long-term employment contracts with any of our employees and do not maintain key employee life insurance.

Continued or increased employee turnover could negatively affect our business.

We have experienced employee turnover as a result of:

• Dependence on lateral hiring of consultants;

• Travel demands imposed on our consultants;

• Loss of employees to competitors and clients; and

• Reductions in force in our business units as certain areas of our business have seen less demand.

Continued or increased employee turnover could materially adversely affect our business and results of operations. In addition, many of our consultants develop strong business relationships with our clients. We depend on these relationships to generate additional assignments and engagements. The loss of a substantial number of consultants could erode our client base and decrease our revenues.

If we are unable to manage shifts in market demand or growth in our business, our business may be negatively impacted.

Our business has historically grown rapidly, and though our overall revenues have remained flat for the past several years, we have experienced growth and increased demand in certain areas of our business. In response to shifts in market demand and in an effort to better align our business with our markets, we restructured our business units and hired persons with appropriate skills, including salespersons, and reduced our workforce in practice areas experiencing less demand. These market conditions and restructuring efforts have placed new and increased demands on our management personnel. It has also placed significant and increasing demands on our financial, technical and operational resources, and on our information systems. If we are unable to manage growth effectively or if we experience business disruptions due to shifts in market demand, or growth or restructuring, our operating results will suffer. To manage any future growth, we must extend our financial reporting and information management systems to our multiple and international office locations and traveling employees, and develop and implement new procedures and controls to accommodate new operations, services and clients. Increasing operational and administrative demands may make it difficult for our senior managers to engage in business development activities and their other day-to-day responsibilities. Further, the addition of new employees and offices to offset any increasing demands may impair our ability to maintain our service delivery standards and corporate culture. In addition, we have in the past changed, and may in the future change, our organizational structure and business strategy. Such changes may result in operational inefficiencies and delays in delivering our services. Such changes could also cause a disruption in our business and could cause a material adverse effect on our financial condition and results of operations.

Changes in the healthcare and pharmaceutical industries could negatively impact our revenues.

We derive a substantial portion of our revenues from clients in the healthcare industry. As a result, our business and results of operations are influenced by conditions affecting this industry, particularly current trends towards consolidation among healthcare and pharmaceutical organizations. Such consolidation may reduce the number of existing and potential clients for our services. In addition, the resulting organizations could have greater bargaining power, which could erode the current pricing structure for our services. The reduction in the size of our target market or our failure to maintain our pricing goals could have a material adverse effect on our business and financial condition. Finally, each of the markets we serve is highly dependent upon the health of the overall economy. Our clients in each of these markets have experienced significant cost increases and pressures in recent years. Our services are targeted at relieving these cost pressures; however, any continuation or acceleration of current market conditions could greatly impact our ability to secure or retain engagements, the loss of which could have a material adverse effect on our business and financial condition.

A substantial portion of our revenues has also come from companies in the pharmaceutical industry. Our revenues are, in part, linked to the pharmaceutical industry’s research and development expenditures. Should any of the following events occur in the pharmaceutical industry, our business could be negatively affected in a material way:

• Continued adverse changes to the industry’s general economic environment;

• Continued consolidation of companies; or

• A decrease in research and development expenditures or pharmaceutical companies’ technology expenditures.

A trend in the pharmaceutical industry is for companies to “outsource” either large information technology-dependent projects or their information systems staffing requirements. We benefit when pharmaceutical companies outsource to us, but may lose significant future business when pharmaceutical

companies outsource to our competitors. If this outsourcing trend slows down or stops, or if pharmaceutical companies direct their business away from us, our financial condition and results of operations could be impacted in a materially adverse way.

Our international operations create specialized risks that can negatively affect us.

We are subject to many risks as a result of the services we provide to our international clients or services we may provide through subcontractors or employees that are located outside of the U.S. Further, in February 2003, we acquired Paragon Solutions, Inc., a U.S. based company with offshore software development centers in India and Vietnam. As a result of this acquisition, we currently have business operations and employees located in India and Vietnam, as well as our existing employees throughout Europe. If we fail to recruit and retain a sufficient number of qualified employees in each country where we conduct business, our ability to perform our existing services may be impaired and our business could be adversely affected. Our international operations are also subject to a variety of risks, including:

• Difficulties in creating international market demand for our services;

• Difficulties and costs of tailoring our services to each individual country’s healthcare and pharmaceutical market needs;

• Uncertainty of cost of labor and high turnover rates;

• Unfavorable pricing and price competition;

• Currency fluctuations;

• Recruiting and hiring employees, and other employment issues unique to international operations, including ability to secure work visas for foreign employees in the U.S.;

• Longer payment cycles in some countries and difficulties in collecting international accounts receivable;

• Terrorist attacks;

• Difficulties in enforcing contractual obligations and intellectual property rights;

• Adverse tax consequences;

• Increased costs associated with maintaining international marketing efforts and offices;

• Government regulations and restrictions;

• Adverse changes in regulatory requirements; and

• Economic or political instability.

We have been performing services in Europe for international clients for several years. We ceased performing healthcare consulting services for European clients in 2000, but continue to provide our services in Europe to pharmaceutical clients. We cannot assure you that we will be able to maintain profitability in our European pharmaceutical services, which may materially adversely affect our financial condition, results of operations, and price for our common stock.

Our acquisition of Paragon Solutions, Inc. provided us a means to implement our global sourcing strategy to provide software development and other information technology services to our clients. If we are unable to realize perceived cost benefits of such a strategy or if we are unable to receive high quality services from foreign employees or subcontractors, our business may be adversely impacted. Further, our recently acquired international operations in Vietnam and India subject our business to a variety of risks and uncertainties unique to operating businesses in these countries, including the risk factors discussed above.

Any one or all of these factors may cause increased operating costs, lower than anticipated financial performance, and may materially adversely affect our business, financial condition, and results of operations.

If we do not compete effectively in the healthcare and pharmaceutical information services industries, our business will be negatively impacted.

The market for healthcare and pharmaceutical information technology consulting is very competitive. We have competitors that provide some or all of the services we provide. For example, in strategic consulting services, we compete with international, regional, and specialty consulting firms such as Bearing Point (formerly KPMG Consulting), Cap Gemini Ernst & Young, IBM Global Consulting Services, Wipro Technologies, and Accenture.

In integration and co-management services, we compete with:

• Information system vendors such as McKesson, Siemens Medical Solutions, Cerner Corporation, and IBM Global Systems,

• Service groups of computer equipment companies,

• Systems integration companies such as Electronic Data Systems Corporation, Perot Systems Corporation, SAIC, Cap Gemini Ernst & Young, and Computer Sciences Corporation,

• Clients’ internal information management departments,

• Other healthcare consulting firms, and

• Other pharmaceutical consulting firms such as Accenture, Cap Gemini Ernst & Young, and Computer Sciences Corporation’s consulting division.

In e-health and e-commerce related services, we compete with the traditional competitors outlined above, as well as newer internet product and service companies. We also compete with companies that provide software development, information technology consulting, and other integration and maintenance services, such as Wipro Technologies, Cognizant Technology Solutions Corporation, and Tata Technologies Limited.

Several of our competitors employ a global sourcing strategy to provide software development and other information technology services to their clients, while at the same time reducing their cost structure and improving the quality of services they provide. If we are unable to realize the perceived cost benefits of our recently implemented global sourcing strategy or if we are unable to receive high quality services from foreign employees or subcontractors, our business may be adversely impacted and we may not be able to compete effectively.

Many of our competitors have significantly greater financial, human, and marketing resources than us. As a result, such competitors may be able to respond more quickly to new or emerging technologies and changes in customer demands, or to devote greater resources to the development, promotion, sale, and support of their products and services than we do. In addition, as healthcare organizations become larger and more complex, our larger competitors may be better able to serve the needs of such organizations. If we do not compete effectively with current and future competitors, we may be unable to secure new and renewed client engagements, or we may be required to reduce our rates in order to compete effectively. This could result in a reduction in our revenues, resulting in lower earnings or operating losses, and otherwise materially adversely affecting our business, financial condition, and results of operations.

If we fail to establish and maintain relationships with vendors of software and hardware products, it could have a negative effect on our ability to secure engagements.

We have a number of relationships with software and hardware vendors. For example, our life sciences business unit is highly dependent upon a non-exclusive relationship with Documentum, Inc., a vendor of document management software applications with which we integrate our FirstDoc ^TM solution. We believe that our relationship with vendors are important to our sales, marketing, and support activities.

We often are engaged by vendors or their customers to implement or integrate vendor products based on our relationship with a particular vendor. If we fail to maintain our relationships with these vendors, or fail to establish additional new relationships, our business could be materially adversely affected.

Our relationships with vendors of software and hardware products could have a negative impact on our ability to secure consulting engagements.

Our growing number of relationships with software and hardware vendors could result in clients perceiving that we are not independent from those software and hardware vendors. Our ability to secure assessment and other consulting engagements is often dependent, in part, on our being independent of software and hardware solutions that we may review, analyze or recommend to clients. If clients believe that we are not independent of those software and hardware vendors, clients may not engage us for certain consulting engagements relating to those vendors, which could reduce our revenues and materially adversely affect our business.

Our business is highly dependent on the availability of business travel.

Our consultants and service providers often reside or work in cities or other locations that require them to travel to a client’s site to perform and execute the client’s project. As a result of the September 11, 2001 terrorist attacks, air travel has become more time-consuming to business travelers due to increased security, flight delays, reduced flight schedules, and other variables. If efficient and cost effective air travel becomes unavailable to our consultants and other employees, or if domestic or international air travel is significantly reduced or halted, we may be unable to satisfactorily perform our client engagements on a timely basis, which could have a materially adverse impact on our business. Further, if our consultants or other employees refuse to utilize air travel to perform their job functions for any reason, our business and reputation would be negatively affected.

If we fail to keep pace with regulatory and technological changes, our business could be materially adversely affected.

The healthcare and pharmaceutical industries are subject to regulatory and technological changes that may affect the procurement practices and operations of healthcare and pharmaceutical organizations. During the past several years, the healthcare and pharmaceutical industries have been subject to an increase in governmental regulation and reform proposals. These reforms could increase governmental involvement in the healthcare and pharmaceutical industries, lower reimbursement rates or otherwise change the operating environment of our clients. Also, certain reforms that create potential work for us could be delayed or cancelled. Healthcare and pharmaceutical organizations may react to these situations by curtailing or deferring investments, including those for our services. In addition, if we are unable to maintain our skill and expertise in light of regulatory or technological changes, our services may not be marketable to our clients and we could lose existing clients or future engagements. Finally, government regulations, particularly HIPAA, may require our clients to impose additional contractual responsibilities on us, which may make it more costly to perform certain of our engagements and subject us to increased risk in the performance of these engagements, including immediate termination of an engagement.

Technological change in the network and application markets has created high demand for consulting, implementation, and integration services. If the pace of technological change were to diminish, we could experience a decrease in demand for our services. Any material decrease in demand would materially adversely affect our business, financial condition, and results of operations.

We may be unable to effectively protect our proprietary information and procedures.

We must protect our proprietary information, including our proprietary methodologies, research, tools, software code, and other information. To do this, we rely on a combination of copyright and trade secret laws and confidentiality procedures to protect our intellectual property. These steps may not protect our proprietary information. In addition, the laws of certain countries do not protect or enforce proprietary rights to the same extent, as do the laws of the United States. We are currently providing our services to clients in international markets and have business operations in Europe, India and Vietnam. Our proprietary information may not be protected to the same extent as provided under the laws of the United States, if at all. The unauthorized use of our intellectual property could have a material adverse effect on our business, financial condition, or results of operations.

We may infringe the intellectual property rights of third parties.

Our success depends, in part, on not infringing patents, copyrights, and other intellectual property rights held by others. We do not know whether patents held or patent applications filed by third parties may force us to alter our methods of business and operation or require us to obtain licenses from third parties. If we attempt to obtain such licenses, we do not know whether we will be granted licenses or whether the terms of those licenses will be fair or acceptable to us. Third parties may assert infringement claims against us in the future. Such claims may result in protracted and costly litigation, penalties, and fines that could adversely affect our business regardless of the merits of such claims.

Our management may be able to exercise control over matters requiring stockholder approval.

Our current officers, directors, and other affiliates beneficially own approximately 32% of our outstanding shares of common stock and approximately 42% on a fully diluted basis. As a result, our existing management, if acting together, may be able to exercise control over or significantly influence matters requiring stockholder approval, including the election of directors, mergers, consolidations, sales of all or substantially all of our assets, issuance of additional shares of stock, and approval of new stock and option plans.

The price of our common stock may be adversely affected by market volatility.

The trading price of our common stock fluctuates significantly. Since our common stock began trading publicly in February 1998, the reported sale price of our common stock on the Nasdaq National Market has been as high as $29.13 and as low as $3.63 per share. This price may be influenced by many factors, including:

• Our performance and prospects;

• The depth and liquidity of the market for our common stock;

• An increase in the number of outstanding shares of our common stock due to issuances in connection with our recent acquisitions;

• Investor perception of us and the industries in which we operate;

• Changes in earnings estimates or buy/sell recommendations by analysts;

• General financial and other market conditions; and

• Domestic and international economic conditions.

In addition, public stock markets have experienced extreme price and trading volume volatility. This volatility has significantly affected the market prices of securities of many companies for reasons frequently unrelated to or disproportionately impacted by the operating performance of these companies. These broad market fluctuations may adversely affect the market price of our common stock. As a result, we may be unable to raise capital or use our stock to acquire businesses on attractive terms and investors may be unable to resell their shares of our common stock at or above their purchase price. Further, if research analysts stop covering our company or reduce their expectations of us, our stock price could

decline or the liquidity of our common stock may be adversely impacted, which could create difficulty for investors to resell their shares of our common stock.

If our stock price is volatile, we may become subject to securities litigation, which is expensive and could result in a diversion of resources.

If our stock price experiences periods of volatility, our security holders may initiate securities class action litigation against us. If we become involved in this type of litigation it could be very expensive and divert our management’s attention and resources, which could materially and adversely affect our business and financial condition.

Our charter documents, Delaware law and stockholders rights plan will make it more difficult to acquire us and may discourage take-over attempts and thus depress the market price of our common stock.

Our board of directors has the authority to issue up to 9,500,000 shares of undesignated preferred stock, to determine the powers, preferences, and rights and the qualifications, limitations, or restrictions granted to or imposed upon any unissued series of undesignated preferred stock and to fix the number of shares constituting any series and the designation of such series, without any further vote or action by our stockholders. The preferred stock could be issued with voting, liquidation, dividend, and other rights superior to the rights of our common stock. Furthermore, any preferred stock may have other rights, including economic rights, senior to our common stock, and as a result, the issuance of any preferred stock could depress the market price of our common stock.

In addition, our certificate of incorporation eliminates the right of stockholders to act without a meeting and does not provide cumulative voting for the election of directors. Our certificate of incorporation also provides for a classified board of directors. The ability of our board of directors to issue preferred stock and these other provisions of our certificate of incorporation and bylaws may have the effect of deterring hostile takeovers or delaying changes in control or management.

We are also subject to the provisions of Section 203 of the Delaware General Corporation Law, which could delay or prevent a change in control of us, impede a merger, consolidation, or other business combination involving us or discourage a potential acquirer from making a tender offer or otherwise attempting to obtain control. Any of these provisions, which may have the effect of delaying or preventing a change in control, could adversely affect the market value of our common stock.

In 1999, our board of directors adopted a share purchase rights plan that is intended to protect our stockholders’ interests in the event we are confronted with coercive takeover tactics. Pursuant to the stockholders rights plan, we distributed “rights” to purchase up to 500,000 shares of our Series A Junior Participating Preferred Stock. Under some circumstances, these rights become the rights to purchase shares of our common stock or securities of an acquiring entity at one-half the market value. The rights are not intended to prevent our takeover, rather they are designed to deal with the possibility of unilateral actions by hostile acquirers that could deprive our board of directors and stockholders of their ability to determine our destiny and obtain the highest price for our common stock.

Item 3. Quantitative and Qualitative Disclosures about Market Risks

Our financial instruments include cash and cash equivalents (i.e., short-term and long-term cash investments), accounts receivable, unbilled receivables, accounts payable, and a revolving line of credit. Only the cash and cash equivalents and investments which totaled $58.5 million at September 26, 2003 present us with market risk exposure resulting primarily from changes in interest rates. Based on this balance, a change of one percent in the interest rate would cause a change in interest income for the annual period of approximately $0.6 million. Our objective in maintaining these investments is the flexibility obtained in having cash available for payment of accrued liabilities and acquisitions.

Our borrowings are primarily dependent upon the prevailing prime rate. As of September 26, 2003, we had no borrowings under our revolving line of credit and an available borrowing capacity of $7.0 million. See “Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations- Liquidity and Capital Resources.” The estimated fair value of borrowings under the revolving line is expected to approximate its carrying value.

Item 4. Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

As required by SEC Rule 13a-15(b), we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and our Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the quarter covered by this report. Based on the foregoing, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level.

There has been no change in our internal controls over financial reporting during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal controls over financial reporting.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings.

None.

Item 2. Changes in Securities.

(c) Sales of Unregistered Securities. On September 26, 2003, we purchased the 15% minority interest of FCG Management Services, LLC held by NYPH for 1.0 million shares of unregistered FCG common stock. The closing price of FCG common stock on September 26, 2003 was $5.10 per share, and the aggregate consideration paid for NYPH’s 15% minority interest on such date was $5.1 million. The shares that were issued are exempt from the registration requirements of the Securities Act of 1933, as amended, pursuant to Section 4(2) of such Act and Rule 506 promulgated thereunder. In connection with our issuance of 1.0 million shares of FCG common stock to New York Presbyterian Hospital (NYPH) for the purchase of its 15% minority interest in FCG Management Services, LLC, NYPH contractually agreed not to sell such FCG common stock until January 1, 2007. After such date, the FCG common stock issued to NYPH will be subject to the resale restrictions established for “affiliates” under Rule 144(k).

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Submission of Matters to a Vote of Security Holders

None.

Item 5. Other Information.

None.

Item 6. Exhibits and Reports on Form 8-K.

(a) Exhibits

Item		Description
3.1 (1)		Certificate of Incorporation of the Company
3.2 (2)		Certificate of Designation of Series A Junior Participating Preferred Stock
3.3 (3)		Bylaws of the Company
4.1 (4)		Specimen Common Stock Certificate
10.1		Letter Agreement by and between the Company and Northern Westchester Hospital Center dated October 1, 2003 regarding the reimbursement of certain interest expenses
10.2		Letter Agreement by and between the Company and Phelps Memorial Hospital Center dated October 1, 2003 regarding the reimbursement of certain interest expenses
10.3		Letter Agreement by and between the Company and Lawrence Hospital Center dated October 1, 2003 regarding the reimbursement of certain interest expenses
10.4		Loan Agreement by and between the Company and White Plains Hospital Center dated October 1, 2003
10.5		Stock Purchase Agreement dated September 17, 2003 by and between FCG Management Services, LLC and The Trustees of the University of Pennsylvania
10.6		Stock Purchase Agreement dated September 26, 2003 by and between the Company and New York Presbyterian Hospital
11.1(5)		Statement of computation of per share earnings
31.1		Certification of Chief Executive Officer
31.2		Certification of Chief Financial Officer
32.1		Certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

(1) Incorporated by reference to Exhibit 3.1 to FCG’s Form S-1 Registration Statement (No. 333-41121) originally filed on November 26, 1997 (the “Form S-1”).

(2) Incorporated by reference to Exhibit 99.1 to FCG’s Current Report on Form 8-K dated December 9, 1999.

(3) Incorporated by reference to Exhibit 3.3 to FCG’s Form S-1.

(4) Incorporated by reference to Exhibit 4.1 to FCG’s Form S-1.

(5) See Note 1 to Consolidated Financial Statements, “Accounting Policies – Basic and Diluted Net Income (Loss) Per Share.”

(b) Reports on Form 8-K

(1) Form 8-K filed on July 24, 2003, furnishing a press release announcing our financial results for the second quarter of 2003 (Items 7 and 9).

(2) Form 8-K filed on September 11, 2003 furnishing a press release announcing our certain organizational changes (Items 7 and 9).

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed in its behalf by the undersigned thereunto duly authorized.

	FIRST CONSULTING GROUP, INC.


Date: November 10, 2003	/s/ LUTHER J. NUSSBAUM
	Luther J. Nussbaum
	Chairman and Chief Executive Officer


Date: November 10, 2003	/s/ WALTER J. MCBRIDE
	Walter J. McBride
	Executive Vice President and Chief Financial Officer
	(Principal Financial Officer)

EXHIBIT INDEX

Item		Description
3.1 (1)		Certificate of Incorporation of the Company
3.2 (2)		Certificate of Designation of Series A Junior Participating Preferred Stock
3.3 (3)		Bylaws of the Company
4.1 (4)		Specimen Common Stock Certificate
10.1		Letter Agreement by and between the Company and Northern Westchester Hospital Center dated October 1, 2003 regarding the reimbursement of certain interest expenses
10.2		Letter Agreement by and between the Company and Phelps Memorial Hospital Center dated October 1, 2003 regarding the reimbursement of certain interest expenses
10.3		Letter Agreement by and between the Company and Lawrence Hospital Center dated October 1, 2003 regarding the reimbursement of certain interest expenses
10.4		Loan Agreement by and between the Company and White Plains Hospital Center dated October 1, 2003
10.5		Stock Purchase Agreement dated September 17, 2003 by and between FCG Management Services, LLC and The Trustees of the University of Pennsylvania
10.6		Stock Purchase Agreement dated September 26, 2003 by and between the Company and New York Presbyterian Hospital
11.1 (5)		Statement of computation of per share earnings
31.1		Certification of Chief Executive Officer
31.2		Certification of Chief Financial Officer
32.1		Certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

(1) Incorporated by reference to Exhibit 3.1 to FCG’s Form S-1 Registration Statement (No. 333-41121) originally filed on November 26, 1997 (the “Form S-1”).

(2) Incorporated by reference to Exhibit 99.1 to FCG’s Current Report on Form 8-K dated December 9, 1999.

(3) Incorporated by reference to Exhibit 3.3 to FCG’s Form S-1.

(4) Incorporated by reference to Exhibit 4.1 to FCG’s Form S-1.

(5) See Note 1 to Consolidated Financial Statements, “Accounting Policies – Basic and Diluted Net Income (Loss) Per Share.”